Experience

Visudyne has more than 5 years of clinical and real-world experience^2,5

Visudyne is the first and only FDA-approved treatment for predominantly classic subfoveal CNV secondary to wet AMD.

In clinical trials, a full course of PDTs with Visudyne resulted in

• Significantly improved visual acuity outcomes vs placebo at 1 and 2 years²

Through clinical and real-world experience, Visudyne has demonstrated a well-established safety profile

• More than 700,000 treatments
• More than 300,000 patients

Along with . . .

• Low incidence of adverse reactions
• Experience in a broad range of patient subtypes including³
• Patients with hypertension
• Patients aged more than 50 years
• Smokers
• Patients with both lower and higher baseline visual acuity

With more than 5 years of clinical and real-world experience combined, Visudyne is a therapy that physicians can rely on to treat with confidence those patients with predominantly classic CNV due to:

• Age-related macular degeneration
• Pathologic myopia
• Presumed ocular histoplasmosis